Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

  • STATUS
    Recruiting
  • participants needed
    200
  • sponsor
    Li Yu
Send
Updated on 16 February 2024
See if I qualify
cancer
remission
solid tumour
solid tumor
immunosuppressive agents
decitabine
cancer treatment
alopecia
cancer therapy
solid neoplasm
malignant solid tumor
malignant solid neoplasm
hair thinning

Summary

  1. Screening stage
  2. Evaluation of disease
  3. Grouping of patients
  4. Infusion of cells
  5. Surveillance of adverse effect

Description

  1. Screening stageAll patients must be confirmed by pathology priorily and reachead remission after surgery or chemo- or radiotherapy. All criteria patients must sign informed consent in advance.
  2. Evaluation of disease: Systematically assessment of tumor burdern and Physical fitness of all patients.
  3. Cell preparationAt least one month after the end of the last chemotherapy, 100ml of peripheral blood was collected, and PBMCs were separated and extracted in the tens of thousands and local hundreds of clean laboratories and DC-CIK cells were prepared.
  4. Baseline assessment: Systematically assess various biochemical indicators. Those who do not meet the infusion criteria will withdraw from the study after being confirmed by researchers.
  5. Study group: All subjects were randomly divided into test group and control group. The test group was treated with decitabine. The course of treatment was a total of 5 times.
  6. InfusionDuring cell culture and before transfusion, cells should be subjected to strict quality control tests such as bacteria, fungi, mycoplasma, endotoxin, cell activity, DC and T cell identification, etc. The transfusion can be approved only after the quality control is qualified.
  7. Adverse reaction monitoring: DC-CIK infusion was used to closely observe changes in subjects' blood pressure, body temperature, blood routine, blood biochemistry, electrolytes, coagulation, cytokines and organ functions.
  8. After the trial is completed, the patient's survival information will be followed up every 3 months by telephone or by visiting the test center.

Details
Condition Cancer
Age 18years - 70years
Treatment Decitabine, DC-CIK
Clinical Study IdentifierNCT04292769
SponsorLi Yu
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male or female patients aged 18-70 years (including 18 and 70 years)
Pathological and histological examination confirmed a malignant solid tumor
Patients with ECOG score <2, estimated survival time> 3 months
Patients with solid tumors have cleared their lesions after treatment, and are unsuitable or unwilling to receive other anti-tumor treatments such as chemotherapy and radiotherapy
Patients did not receive any anti-cancer treatment such as chemotherapy, radiotherapy, immunotherapy (such as immunosuppressive drugs) within 2-4 weeks before enrollment, and their previous treatment-related toxicities have recovered to <1 (hair loss) , Except for low-level toxicity such as peripheral neuritis)
The patient's venous channel is unobstructed, which can meet the needs of intravenous drip
Patients voluntarily participate and sign informed consent, and follow the research treatment plan and visit plan

Exclusion Criteria

\. Patients use large doses of hormones (except for patients using inhaled hormones) within 1 week before enrollment; 2. People with severe autoimmune diseases, immunodeficiency diseases or severe allergies; 3. Patients treated with other cellular immune products (DC, T, NK, and CAR-T, etc.); 4. Patients have uncontrollable infections within 4 weeks before enrollment; 5. Active HBV DNA> 1000copy / mL / Hepatitis C virus (anti-HCV positive, HCV RNA positive), HIV positive, syphilis positive; 6. Patients participated in other clinical studies within 6 weeks before enrollment; 7. Patients with mental illness; 8. Patients with a substance abuse / addiction and medical, psychological or social conditions that may interfere with the study or influence the evaluation of the study results; 9. Alcohol dependence in patients; 10. Women who are pregnant (positive urine / blood pregnancy study) or breastfeeding; men or women with a pregnancy plan in the past year; patients cannot guarantee effective contraception during the study period 11. At the discretion of the investigator, the patient has other unsuitable conditions
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
remission
solid tumour
solid tumor
immunosuppressive agents
decitabine
cancer treatment
alopecia
cancer therapy
solid neoplasm
malignant solid tumor
malignant solid neoplasm
hair thinning

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.